Skip to main content
Toggle navigation
Login
Search
Home
iwCLL X / Twitter
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Tweet
Sasanka M. Handunnetti, MBBS, PhD
Consultant Haematologist
Princess Alexandra Hospital, Australia
NA
Poster(s):
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
